May 31, 2024
Thousands of cancer patients in England will gain fast-tracked access to trials of personalized cancer vaccines following the launch of an NHS trial “matchmaking” service to find life-saving treatments. The investigational cancer vaccines evaluated in the colorectal cancer trial are based on mRNA - the same technology used for the Pfizer-BioNTech COVID-19 vaccine - and are created by analyzing a patient’s tumour to identify mutations specific to their own cancer. The developmental vaccines are designed to induce an immune response that may prevent cancer from returning after surgery on the primary tumour, by stimulating the patient’s immune system to specifically recognize and potentially destroy any remaining cancer cells.
Full article link